Trial Profile

A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemcentinib (Primary) ; Erlotinib
Indications Non-small cell lung cancer
Focus Adverse reactions
Sponsors BerGenBio

Most Recent Events

08 Jun 2021 Status changed from recruiting to completed, as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
08 Jun 2021 Results (data cut off date- 7 Oct 2020) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
22 Oct 2018 Results published in a BerGenBio media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com